Ophthotech price target raised to $45 from $37 at Leerink Leerink raised its price target for Ophthotech shares to $45 citing Fovista and Zimura pipeline advancement. The firm reiterates an Outperform rating on the stock.
News For OPHT From The Last 14 Days
Check below for free stories on OPHT the last two weeks.
Ophthotech earlier than expected Novartis payment positive, says Oppenheimer After Ophthotech (OPHT) received a $50M Phase 3 enrollment payment from Novartis (NVS) earlier than expected, Oppenheimer thinks the payment highlights an underappreciated stock driver for Opthotech, and demonstrates that recent suggestions of Phase 3 enrollment timelines possibly slipping are unwarranted. The firm believes the company is executing well on the Fovista Phase 3 program and keeps an Outperform rating on the stock.